Back to today’s briefing

Story perspectives

Neumora's Navacaprant Fails Phase 3 Trial, Stock Plummets 80%

1/2/2025

32 4

Summary

Story summary

Neumora Therapeutics' navacaprant did not demonstrate significant efficacy in the Phase 3 KOASTAL-1 trial for major depressive disorder.
Both treatment and placebo groups experienced a 12.5-point reduction in depression scores.
The drug was well-tolerated, with no serious adverse events reported.
Ongoing studies KOASTAL-2 and KOASTAL-3 are anticipated to provide results soon.
Following the announcement, Neumora's stock plummeted over 80%.

1 of 1

Story summary

Neumora Therapeutics' navacaprant did not demonstrate significant efficacy in the Phase 3 KOASTAL-1 trial for major depressive disorder.
Both treatment and placebo groups experienced a 12.5-point reduction in depression scores.
The drug was well-tolerated, with no serious adverse events reported.
Ongoing studies KOASTAL-2 and KOASTAL-3 are anticipated to provide results soon.
Following the announcement, Neumora's stock plummeted over 80%.